Jeffrey Hubbell, Ph.D.

AIMBE College of Fellows Class of 1995
For fundamental and clinically-applied contributions to biomaterials.

Jeffrey Hubbell elected to National Academy of Sciences

Via University of Chicago | May 4, 2023

Three UChicago faculty members elected to National Academy of Sciences in 2023

Three University of Chicago scholars have been elected to the National Academy of Sciences, in recognition of their distinguished scientific research achievements.

Profs. Jeffrey Hubbell, Anthony A. Kossiakoff and Eduardo A. Perozo are among the 120 new members elected this year. Another 23 international members were recognized in the May 2 announcement… Continue reading.

New treatment could prevent anaphylactic reactions

Via New Food Magazine | August 23, 2022

A new treatment could prevent hypersensitive consumers from having dangerous anaphylactic reactions if they consume an allergen by replacing important gut bacteria.

Although many people with dietary allergies experience mild symptoms when exposed to triggering foods, some face potentially fatal consequences as a result of anaphylactic reactions. A bacterial compound called butyrate that’s made by healthy microbiomes has shown promise against allergic reactions in lab tests, but it’s not nice to take orally.

But now scientists at the University of Chicago are working on a more palatable way to deliver this compound and report that their “polymeric micelles” are effective against peanut allergies in mice. The treatment could someday counteract many types of food allergies and inflammatory diseases… Continue reading.

UChicago researchers find way to improve multiple sclerosis treatment

Via University of Chicago | October 12, 2020

Multiple sclerosis, an autoimmune disease of the central nervous system that affects millions worldwide, can cause debilitating symptoms for those who suffer from it.

Though treatments exist, researchers are still searching for therapies that could more effectively treat the disease, or even prevent it altogether.

Researchers at the Pritzker School of Molecular Engineering (PME) at the University of Chicago have designed a new therapy for multiple sclerosis (MS) by fusing a cytokine to a blood protein. In mice, this combination prevented destructive immune cells from infiltrating the central nervous system and decreased the number of cells that play a role in MS development, leading to fewer symptoms and even disease prevention… Continue reading.

Breakthrough helps fight ‘cold’ tumors that don’t respond to immunotherapy

Via University of Chicago | April 30, 2020

Immunotherapy, which unleashes the power of the body’s own immune system to find and destroy cancer cells, has shown promise in treating several types of cancer.

But the disease is notorious for cloaking itself from the immune system, and tumors that are not inflamed and do not elicit a response from the immune system—so-called “cold” tumors—do not respond to immunotherapies.

Researchers at the Pritzker School of Molecular Engineering at the University of Chicago have taken a step toward solving this problem with an innovative immunotherapy delivery system. The system finds tumors by seeking out and binding to the tumors’ collagen, then uses a protein called IL-12 to inflame the tumor and activate the immune system, thereby activating immunotherapy… Continue reading.

New vaccine for malaria developed at IME could be more effective

Via University of Chicago | February 1, 2019

Researchers at the Institute for Molecular Engineering at the University of Chicago have developed an innovative new system for delivering a malaria vaccine that shows promise in its effectiveness. By developing a vaccine that targets specific cells in the immune system, they have seen a much greater immune and antibody response to the vaccine.

Though a vaccine for malaria exists, it is only effective in 30 percent to 50 percent of patients, and malaria is still responsible for nearly 500,000 deaths annually, according to the Centers for Disease Control.

“When compared to the current malaria vaccine option, our results are extremely exciting,” said Jeffrey Hubbell, the Eugene Bell Professor in Tissue Engineering, a pioneering researcher and early entrepreneur in the field of tissue engineering. Hubbell co-authored a paper that was recently published in Nature Materials. “This work could potentially have applications in vaccinations against complex infections and cancer… Continue reading.

Overcoming Immunological Barriers in Regenerative Medicine

Via Nature | August 4, 2014

Regenerative therapies that use allogeneic cells are likely to encounter immunological barriers similar to those that occur with transplantation of solid organs and allogeneic hematopoietic stem cells (HSCs). Decades of experience in clinical transplantation hold valuable lessons for regenerative medicine, offering approaches for developing tolerance-induction treatments relevant to cell therapies. Outside the field of solid-organ and allogeneic HSC transplantation, new strategies are emerging for controlling the immune response, such as methods based on biomaterials or mimicry of antigen-specific peripheral tolerance. Novel biomaterials can alter the behavior of cells in tissue-engineered constructs and can blunt host immune responses to cells and biomaterial scaffolds. Approaches to suppress autoreactive immune cells may also be useful in regenerative medicine. The most innovative solutions will be developed through closer collaboration among stem cell biologists, transplantation immunologists and materials scientists.

Four Advanced ERC Grants for Our SV Professors

Via École Polytechnique Fédérale De Lausanne | October 4, 2013

Four professors leading research groups at the Faculty of Life Sciences have been awarded an ADVANCED GRANT 2013 from the European Research Council (ERC), in recognition of their outstanding research performed at the EPFL…

…Jeffrey Hubbell, head of the Laboratory of Regenerative Medicine & Pharmacobiology (Merck Serono Chair in Drug Delivery), for his research on Engineering Cytokines for Super-Affinity Binding to Matrix in Regenerative Medicine.

Autoimmune disease – Retraining White Blood Cells

Via École Polytechnique Fédérale De Lausanne | December 18, 2012

Engineering antigens for in situ erythrocyte binding induces T-cell deletion.

“Antigens derived from apoptotic cell debris can drive clonal T-cell deletion or anergy, and antigens chemically coupled ex vivo to apoptotic cell surfaces have been shown correspondingly to induce tolerance on infusion. Reasoning that a large number of erythrocytes become apoptotic (eryptotic) and are cleared each day, the group of Prof. Jeffrey Alan Hubbell (Merck Serono Chair in Drug Delivery) engineered two different antigen constructs to target the antigen to erythrocyte cell surfaces after i.v. injection, one using a conjugate with an erythrocyte-binding peptide and another using a fusion with an antibody fragment, both targeting the erythrocyte-specific cell surface marker glycophorin A. They report a translatable modular biomolecular approach with which to engineer antigens for targeted binding to erythrocyte cell surfaces to induce antigen-specific CD4+ and CD8+ T-cell deletion toward exogenous antigens and autoantigens.”

Autoimmune Disease – Retraining White Blood Cells

Via École Polytechnique Fédérale De Lausanne | December 18, 2012

Symptoms of an autoimmune disease disappeared after a team of scientists retrained white blood cells using a specially engineered protein. This method is extremely promising for treating diseases such as type I diabetes and multiple sclerosis.

How can the immune system be reprogrammed once it starts to attack its own body? EPFL scientists retrained white blood cells responsible for type I diabetes, a common autoimmune disease. Using a modified protein, they precisely targeted these white blood cells (T-lymphocytes, or T-cells) that were attacking pancreatic cells and causing the disease. When tested on laboratory mice, the therapy eliminated all signs of the pathology. This same method could be extremely promising in treating multiple sclerosis as well. The scientists have just launched a start-up Anokion SA on the Lausanne campus, and are planning to conduct clinical trials within the next two years. Their discovery has been published in the journal PNAS (Proceedings of the National Academy of Science).

To retrain the rebellious white blood cells, the researchers began with a relatively simple observation. Every day, thousands of our cells die. Each time a cell expires, it sends out a message to the immune system. If the death is caused by trauma, such as inflammation, the message tends to stimulate white blood cells to become aggressive. But if the cell dies a programmed death at the end of its natural life cycle, it sends out a calming signal.

In the human body there is a type of cell that dies off profusely, at the order of 200 billion per day: red blood cells. There are as many calming signals transmitted daily to the immune system.

The scientists therefore attached the pancreatic protein targeted by T-cells in type I diabetes to red blood cells. “Our idea was that by associating the protein under attack to a soothing event, like the programmed death of red blood cells, we would reduce the intensity of the immune response,” explains Jeffrey Hubbell, co-author of the study. To do this, the researchers opted for state-of-the-art bioengineering: the protein, equipped, with a hook of molecular size, is able to attach itself to red blood cells. Billions of these were manufactured and then simply injected into the body.

New Vaccine that Elicit Pulmonary Cytotoxic T Cell Responses

Via École Polytechnique Fédérale De Lausanne | November 2, 2011

Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination.

Disulfide-linked nanoparticle-antigen conjugates could be useful for creating vaccines that elicit pulmonary cytotoxic T cell responses. As shown by the groups of Prof. Jeffrey Hubbell (LMRP – Merck Serono Chair in Drug Delivery) and Prof. Melody Swartz (LLCB – Laboratory of Lymphatic and Cancer Bioengineering), intranasal delivery of a model antigen linked to a nanoparticle increased Cd8+ T cell responses and improved protection against an engineered influenza strain compared with unconjugated antigen in mice. Next steps will include testing the vaccine in additional pulmonary indications, including lung cancer and tuberculosis.